the strongest research behind it. Multiple private insurers established reimbursement for the Oncotype DX AR-V7 Nucleus Detect test, bringing the total number of U.S. covered lives to more than 75 million, including, Additional private insurers established reimbursement for the Oncotype DX Breast Recurrence Score test in patients with 1-3 positive nodes, bringing the total number of U.S. covered lives in this breast cancer population to more than 144 million, including.
The company is based in Redwood City, California, with international headquarters in Geneva, Switzerland.

› Url: https://newsroom.genomichealth.com/news-releases/news-release-details/genomic-health-reports-19-revenue-growth-and-record-profit Go Now, Health Details: Physician Portal. Access results Inconclusive by IHC. In rare cases, the diagnostic needle core biopsy may be the optimal sample for testing than the excisional sample; if this is the case, then the needle core biopsy should be submitted. Please fill out each section of the requisition form completely. Hear how breast cancer survivors personalized their cancer treatment with Oncotype DX. Sign up here to receive news alerts from Genomic Health. REDWOOD CITY, Calif., Jan. 7, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that, in collaboration with physicians around the world, it has delivered more than 1 million Oncotype DX ® tests to cancer patients worldwide since it made its first test available to patients in 2004. How does it compare to other genomic tests? ER STATUS: q. Healthcare Professionals > Oncotype DX Breast Recurrence Score. These risks and uncertainties include, but are not limited to: the results of clinical studies, including the TAILORx study; the applicability of clinical study results to actual outcomes; the ability of the test results to change treatment decisions and improve patient outcomes; the risks and uncertainties associated with the regulation of the company's tests; the risk that the company may not obtain or maintain sufficient levels of reimbursement, domestically or abroad, for its existing tests and any future tests it may develop; the risks of competition; unanticipated costs or delays in research and development efforts; and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2018.

Radiation therapy may be recommended for some women. NODE STATUS: q.

Kit orders are usually processed within a day and received within 48 hours. Learn more about the results report and how to interpret the results. NPI record contains FOIA-disclosable NPPES health care provider information. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary. More than one million patients tested worldwide. Oncotype DX test results assign a Recurrence Score — a number between 0 and 100 — to the early-stage breast cancer or DCIS. Watch how Genomic Health continues to transform cancer care around the world. The 1215003603 NPI number is assigned to the healthcare provider “GENOMIC HEALTH INC.”, practice location address at “301 PENOBSCOT DRIVE BILLING AND REIMBURSEMENT OPS.
Learn more about our commitment to providing complete, accurate, and private breast cancer information. After surgery, hormonal therapies such as an aromatase inhibitor or tamoxifen are prescribed to reduce the risk that the cancer will come back in the future. The company's flagship product, the Oncotype DX Breast Recurrence Score® test, is the only test that has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer.

Health Details: Genomic Health is expanding its test portfolio to include additional liquid- and tissue-based tests, including the Oncotype DX ® AR-V7 Nucleus Detect™ test. ixLayer enables leading health systems, clinical labs, biopharma, and consumer companies to offer precision health testing. SPECIMEN INSTRUCTIONS Specimen Preparation Instructions GHI is able to accept specimens from most countries outside of the US for the Oncotype DX Cancer Assay. Watch CEO Kim Popovits and others discuss the motivation, inspiration, and rewards of working at Genomic Health, as well as the company's vision for the future. Health Details: Oncotype DX test. Together, you can make a decision about whether or not you should have chemotherapy or radiation therapy. [7], In July 2005 Genomic Health filed for an initial public offering to sell up to US$75,000,000 in common stock. For insurance- and payment-related questions, call 1-866-ONCOTYPE (1-866-662-6897) or email customerservice@genomichealth.com. The Scramble To Cash In On the Genome", "Exact Sciences to Buy Genomic Health for About $2.8 Billion", https://en.wikipedia.org/w/index.php?title=Genomic_Health&oldid=959108174, Health care companies established in 2000, Health care companies based in California, Companies based in Redwood City, California, Creative Commons Attribution-ShareAlike License, This page was last edited on 27 May 2020, at 05:33. ... Fax Us Mail Us Email Us Support; Help Site Map Site Tour Web ... › Url: https://med.noridianmedicare.com/web/jfb/article-detail/-/view/10534/moldx-genomic-health-oncotype-dx-prostate-cancer-assay-lcd-r6 Go Now.

Create a profile for better recommendations. Prepaid expenses and other current assets, Accrued expenses and other current liabilities, Current portion of operating lease liabilities, Total liabilities and stockholders' equity. The company is based in Redwood City , California, with international headquarters in Geneva, Switzerland. Primary study group results were presented at ASCO 2018. Studies have shown that Oncotype DX is useful for both purposes. The Medicare program and several other major insurance companies have agreed to cover the Oncotype DX test. q. About Genomic Health Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that help optimize cancer care, including addressing the overtreatment of the disease, one of the greatest issues in healthcare today. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's beliefs regarding its future performance, including updated 2019 financial guidance; the company's beliefs regarding its revenue growth for the remainder of 2019 and the drivers of growth; the company's belief regarding its ability to generate half a billion dollars in revenue in 2020; and the company's expectations regarding additional public and private reimbursement coverage for its tests worldwide and the ability of additional coverage to result in additional revenue. Breastcancer.org’s EIN is 23-3082851. Be a part of the world's leading provider of genomic cancer diagnostic tests. › Url: https://finance.yahoo.com/news/genomic-health-posts-impressive-data-145902493.html Go Now.